Casey A Maguire
Overview
Explore the profile of Casey A Maguire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
3161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng M, Cruz D, Crain A, Espinoza P, Ng C, Elmore Z, et al.
Mol Ther Methods Clin Dev
. 2025 Feb;
33(1):101407.
PMID: 40008086
Extracellular vesicle-associated adeno-associated virus vectors (EV-AAVs) are generated during production in 293 cells. EV-AAV provides desirable gene delivery traits such as greater resistance to antibody neutralization and increased transduction of...
2.
Espinoza P, Cheng M, Ng C, Cruz D, Wasson E, McCarthy D, et al.
Metab Eng
. 2024 Dec;
88:40-49.
PMID: 39653070
Adeno-associated viruses (AAV) are promising vectors for gene therapy due to their efficacy in vivo. However, there is room for improvement to address key limitations such as the pre-existing immunity...
3.
Alves C, Das S, Krishnan V, Ha L, Fox L, Stutzman H, et al.
bioRxiv
. 2024 Nov;
PMID: 39605323
Genetic vascular disorders are prevalent diseases that have diverse etiologies and few treatment options. Pathogenic missense mutations in the alpha actin isotype 2 gene () primarily affect smooth muscle cell...
4.
Nieland L, Vrijmoet A, Jetten I, Rufino-Ramos D, de Reus A, Breyne K, et al.
Mol Ther
. 2024 Nov;
33(1):133-151.
PMID: 39563028
Glioblastoma (GB), the most aggressive tumor of the central nervous system (CNS), has poor patient outcomes with limited effective treatments available. MicroRNA-21 (miR-21(a)) is a known oncogene, abundantly expressed in...
5.
Vasireddy V, Maguire C, Anderson D, Ng C, Gong Y, Eichler F, et al.
Mol Ther Methods Clin Dev
. 2024 Nov;
32(4):101354.
PMID: 39524975
Adrenomyeloneuropathy is a progressive neurodegenerative disease caused by pathogenic variants in the gene, resulting in very-long-chain fatty acid (VLCFA) accumulation that leads to dying-back axonopathy. Our candidate gene therapy, SBT101...
6.
Santoscoy M, Espinoza P, Hanlon K, Yang L, Nieland L, Ng C, et al.
bioRxiv
. 2024 Oct;
PMID: 39386560
Microglia are critical innate immune cells of the brain. targeting of microglia using gene-delivery systems is crucial for studying brain physiology and developing gene therapies for neurodegenerative diseases and other...
7.
Herre M, Vemuri K, Cedervall J, Nissl S, Saupe F, Micallef J, et al.
FASEB Bioadv
. 2024 Oct;
6(10):454-466.
PMID: 39372124
Neutrophil extracellular traps (NETs) have been implicated in the pathology of various inflammatory conditions. In cancer, NETs have been demonstrated to induce systemic inflammation, impair peripheral vessel and organ function...
8.
Espinoza P, Cheng M, Ng C, Cruz D, Wasson E, McCarthy D, et al.
bioRxiv
. 2024 Sep;
PMID: 39229172
Adeno-associated viruses (AAV) are promising vectors for gene therapy due to their efficacy in vivo. However, there is room for improvement to address key limitations such as the pre-existing immunity...
9.
Hanlon K, Cheng M, Ferrer R, Ryu J, Lee B, Cruz D, et al.
Mol Ther
. 2024 Jun;
32(8):2584-2603.
PMID: 38845196
Systemic administration of adeno-associated virus (AAV) vectors for spinal cord gene therapy has challenges including toxicity at high doses and pre-existing immunity that reduces efficacy. Intrathecal (IT) delivery of AAV...
10.
Prabhakar S, Beauchamp R, Cheah P, Yoshinaga A, Haidar E, Lule S, et al.
Mol Ther Methods Clin Dev
. 2024 May;
32(2):101262.
PMID: 38745896
[This corrects the article DOI: 10.1016/j.omtm.2022.06.012.].